Conference Reports for NATAP

IAS 2013: 7th IAS Conference on HIV Pathogenesis Treatment and Prevention June 30 - July 3 2013 Kuala Lumpur, Malaysia Back

Maraviroc Safety & Efficacy in Children Aged 2-18       Reported by Jules Levin IAS 2013 June 30-July 3 Kuala Lumpur   IAS: Efficacy and Tolerability of Maraviroc for Children With Antiretroviral Experience - written by Mark Mascolini - (07/01/13)   Link to webcast: http://pag.ias2013.org/flash.aspx?pid=67   CONCLUSIONS   ·These data suggest that in HIV-1-infected, treatment-experienced children aged 2 - <18 years, MVC (administered twice-daily) in addition to OBT was:   ÐGenerally well-tolerated   ÐEffective at 48 wks, with 52% and 40% of subjects achieving HIV-1 RNA < 400 copies/mL and < 48 copies/mL, respectively   ·Virological failure was associated with non adherence and was more frequent in adolescents (Cohort 4)   ·Enrolment is continuing with collection of additional data, including OBT resistance, out to 5 years